Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study
- PMID: 25585033
- PMCID: PMC4416978
- DOI: 10.1176/appi.ajp.2014.14040480
Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study
Abstract
Objective: Little is known about factors influencing the rate of progression of Alzheimer's dementia. Using data from the Cache County Dementia Progression Study, the authors examined the link between clinically significant neuropsychiatric symptoms in mild Alzheimer's dementia and progression to severe dementia or death.
Method: The Cache County Dementia Progression Study is a longitudinal study of dementia progression in incident cases of this condition. Survival analyses included unadjusted Kaplan-Meier plots and multivariate Cox proportional hazard models. Hazard ratio estimates controlled for age at dementia onset, dementia duration at baseline, gender, education level, General Medical Health Rating, and apolipoprotein E epsilon 4 genotype.
Results: Three hundred thirty-five patients with incident Alzheimer's dementia were studied. Sixty-eight (20%) developed severe dementia over the follow-up period. Psychosis (hazard ratio=2.007), agitation/aggression (hazard ratio=2.946), and any one clinically significant neuropsychiatric symptom (domain score ≥4, hazard ratio=2.682) were associated with more rapid progression to severe dementia. Psychosis (hazard ratio=1.537), affective symptoms (hazard ratio=1.510), agitation/aggression (hazard ratio=1.942), mildly symptomatic neuropsychiatric symptoms (domain score of 1-3, hazard ratio=1.448), and clinically significant neuropsychiatric symptoms (hazard ratio=1.951) were associated with earlier death.
Conclusions: Specific neuropsychiatric symptoms are associated with shorter survival time from mild Alzheimer's dementia to severe dementia and/or death. The treatment of specific neuropsychiatric symptoms in mild Alzheimer's dementia should be examined for its potential to delay time to severe dementia or death.
Figures
Comment in
-
Neuropsychiatric symptoms in dementia: a cause or consequence?Am J Psychiatry. 2015 May;172(5):410-1. doi: 10.1176/appi.ajp.2015.15030277. Am J Psychiatry. 2015. PMID: 25930129 No abstract available.
Similar articles
-
Neuropsychiatric Symptoms as Risk Factors for Cognitive Decline in Clinically Normal Older Adults: The Cache County Study.Am J Geriatr Psychiatry. 2020 Jan;28(1):64-71. doi: 10.1016/j.jagp.2019.03.023. Epub 2019 May 23. Am J Geriatr Psychiatry. 2020. PMID: 31186157 Free PMC article.
-
Predictors of progression to severe Alzheimer's disease in an incidence sample.Alzheimers Dement. 2013 Mar;9(2):204-7. doi: 10.1016/j.jalz.2012.01.003. Epub 2012 Nov 2. Alzheimers Dement. 2013. PMID: 23123228 Free PMC article.
-
The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease.Am J Geriatr Psychiatry. 2013 Jul;21(7):685-95. doi: 10.1016/j.jagp.2013.01.006. Epub 2013 Feb 6. Am J Geriatr Psychiatry. 2013. PMID: 23567400 Free PMC article.
-
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2. Cochrane Database Syst Rev. 2021. PMID: 34918337 Free PMC article. Review.
-
Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease.Ageing Res Rev. 2012 Jan;11(1):87-103. doi: 10.1016/j.arr.2011.06.005. Epub 2011 Jul 7. Ageing Res Rev. 2012. PMID: 21763789 Review.
Cited by
-
Healthcare Resource Utilization Among Patients With Agitation in Alzheimer Dementia.J Health Econ Outcomes Res. 2024 Oct 29;11(2):118-124. doi: 10.36469/001c.124455. eCollection 2024. J Health Econ Outcomes Res. 2024. PMID: 39507604 Free PMC article.
-
Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms.Geroscience. 2024 Sep 27. doi: 10.1007/s11357-024-01359-x. Online ahead of print. Geroscience. 2024. PMID: 39331291 Review.
-
Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling.Front Pharmacol. 2024 Sep 12;15:1474868. doi: 10.3389/fphar.2024.1474868. eCollection 2024. Front Pharmacol. 2024. PMID: 39329116 Free PMC article.
-
Associations Between Neuropsychiatric Symptoms and Inflammation in Neurodegenerative Dementia: A Systematic Review.J Inflamm Res. 2024 Sep 7;17:6113-6141. doi: 10.2147/JIR.S385825. eCollection 2024. J Inflamm Res. 2024. PMID: 39262651 Free PMC article. Review.
-
Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy - a cross-sectional study.Alzheimers Res Ther. 2024 Sep 4;16(1):196. doi: 10.1186/s13195-024-01519-3. Alzheimers Res Ther. 2024. PMID: 39232823 Free PMC article.
References
-
- Rabins P, Lyketsos C, Steele C. Practical Dementia Care. 2nd ed. New York: Oxford University Press; 2006.
-
- Alzheimer's Association. 2012 Alzheimer's Disease Facts and Figures. 2012. - PubMed
-
- Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R. Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimers Dement. 2010 Nov;6(6):431–439. - PubMed
-
- Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai WY. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997 Mar 12;277(10):806–812. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
